Market-Moving News for September 8th
Portfolio Pulse from ryanfaloona@benzinga.com
Plus Therapeutics licenses diagnostic assay to detect central nervous system cancers, causing BIOC to rise by 79%. DA Davidson initiates coverage on Snowflake with a buy rating and a price target of $200, leading to a 3% increase in SNOW. Grom Social Enterprises announces pricing of $3M public offering of 946,000 units at $3.00 per unit, resulting in a 53% drop in GROM.
September 08, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Plus Therapeutics' licensing of a diagnostic assay led to a 79% increase in BIOC.
The licensing of the diagnostic assay by Plus Therapeutics is a positive development for BIOC, leading to increased investor confidence and a surge in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
DA Davidson initiated coverage on Snowflake with a buy rating and a price target of $200, causing a 3% increase in SNOW.
The initiation of coverage by DA Davidson with a buy rating and a price target of $200 is a positive signal for SNOW, leading to increased investor interest and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Grom Social Enterprises' announcement of a $3M public offering of 946,000 units at $3.00 per unit led to a 53% drop in GROM.
The announcement of a $3M public offering at $3.00 per unit by Grom Social Enterprises is a negative development for GROM, leading to decreased investor confidence and a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100